Roivant ends longshot lupus program after phase 2 fail

cafead

Administrator
Staff member
  • cafead   Nov 28, 2023 at 11:02: AM
via Roivant’s CEO Matt Gline always knew the lupus drug brepocitinib was a longshot: “Anybody who is not afraid of a lupus study is an idiot, you shouldn’t trust them,” he told Fierce Biotech at the beginning of the year.

article source
 

<